Philippe brings over 30 years of pharmaceutical industry expertise to ProTransit, with a deep understanding of market dynamics, stakeholder engagement, and early-stage commercialization. Known for his strategic, value-driven approach, Philippe has led major product launches and divisions at blue chip pharma companies and start-ups. His experience includes Rogaine® at Pharmacia & Upjohn, launching Xenical® (orlistat, now Alli®) for weight loss, founding and running a cosmeceutical start-up at Hoffmann-La Roche, and leading the Dermatology/Topicals Division at Valeant-Medicis-Obagi. Philippe earned his BA from Middlebury College in Vermont. His most recent focus is on commercializing market-disruptive microparticle drug delivery platforms for a wide range of diseases and conditions with high unmet needs for better, faster and safer clinical outcomes.
Philippe Burnham
